{
    "nct_id": "NCT00479219",
    "title": "A Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSI-953 in Blood and Cerebrospinal Fluid, When Administered Orally to Healthy Young Subjects and Patients With Alzheimer Disease",
    "status": "COMPLETED",
    "last_update_time": "2008-07-09",
    "description_brief": "To assess the pharmacodynamics (PD) of biomarkers amyloid beta peptide 40 and 42 (Ab40 and Ab42) in CSF, following single oral doses of GSI-953, an investigational drug, in healthy young subjects and patients with Alzheimer Disease (AD).",
    "description_detailed": "N/A",
    "phase": [
        "PHASE1"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "disease-targeted small molecule",
    "drug": [
        "GSI-953 (begacestat) \u2014 a small\u2011molecule, selective gamma\u2011secretase inhibitor targeting APP cleavage and reducing A\u03b240/A\u03b242"
    ],
    "placebo": [],
    "explanation_target": [
        "Reason: The trial tests GSI-953 with pharmacodynamic readouts of A\u03b240 and A\u03b242 in CSF after single oral doses, indicating the intended effect is to lower amyloid peptide production by inhibiting the \u03b3\u2011secretase cleavage of APP \u2014 a disease\u2011modifying approach targeting Alzheimer pathology rather than symptomatic cognitive enhancement or neuropsychiatric management. \ue200cite\ue202turn0search1\ue202turn0search3\ue201",
        "Act: Key extracted details \u2014 the investigational drug GSI-953 is begacestat, a thiophene sulfonamide small\u2011molecule \u03b3\u2011secretase inhibitor that selectively inhibits APP cleavage (reducing A\u03b240/A\u03b242) over Notch and has shown dose\u2011dependent changes in plasma (and PD biomarker assessments in CSF/brain) after oral dosing in humans and animals. This matches a disease\u2011targeted small\u2011molecule mechanism. \ue200cite\ue202turn0search1\ue202turn0search0\ue202turn0search2\ue201",
        "Web search results (sources used): PubMed entry and preclinical/clinical profile describing begacestat (GSI\u2011953) as a selective \u03b3\u2011secretase inhibitor that lowers A\u03b240/A\u03b242 (PubMed abstract). \ue200cite\ue202turn0search1\ue201; Alzheimer\u2019s & Dementia/meeting abstract and JPET article reporting PK/PD biomarker relationships and single\u2011dose human PD (plasma/CSF A\u03b2) with GSI\u2011953. \ue200cite\ue202turn0search0\ue202turn0search3\ue201",
        "Reflect: Classification check \u2014 given GSI\u2011953 is a small\u2011molecule \u03b3\u2011secretase inhibitor aimed at reducing amyloid \u03b2 peptide production (disease pathology), the correct category is 'disease-targeted small molecule'. There is no indication this trial is testing a biologic (e.g., monoclonal antibody), a pure cognitive enhancer, or a neuropsychiatric symptomatic treatment. No ambiguity found in the provided description or cited literature."
    ],
    "agent_type": "A) Amyloid beta",
    "explanation_agent": [
        "Reason: The investigational drug GSI-953 (begacestat) is described and documented as a small\u2011molecule, thiophene sulfonamide \u03b3\u2011secretase inhibitor that selectively inhibits APP cleavage to reduce production of A\u03b240/A\u03b242 peptides \u2014 i.e., it acts on the amyloid\u2011beta production pathway rather than on symptomatic neurotransmission or unrelated processes. \ue200cite\ue202turn0search3\ue202turn0search0\ue201",
        "Act: Extracted details from the trial description and literature \u2014 drug name: GSI\u2011953 (begacestat); mechanism: selective \u03b3\u2011secretase inhibition of APP cleavage (low\u2011nanomolar potency) with demonstrated dose\u2011dependent lowering of A\u03b240/A\u03b242 in plasma, brain and in some studies CSF after oral dosing in animals and humans; selectivity for APP versus Notch cleavage is reported (\u224815\u201316\u00d7). These points map directly to CADRO category A (Amyloid beta). \ue200cite\ue202turn0search1\ue202turn0search4\ue201",
        "Reflect: Classification check \u2014 the trial\u2019s PD readouts (A\u03b240/A\u03b242 in CSF and plasma) and the drug\u2019s explicit mechanism (blocking \u03b3\u2011secretase to lower A\u03b2 production) make A) Amyloid beta the most specific and appropriate CADRO category. There is no indication the intervention targets tau, inflammation, synaptic plasticity, metabolism, or other CADRO categories, nor is it a diagnostic/non\u2011therapeutic procedure. \ue200cite\ue202turn0search3\ue201",
        "Web search results (sources used): 1) JPET article and abstract describing begacestat (GSI\u2011953) as a selective \u03b3\u2011secretase inhibitor that lowers A\u03b2 in brain, plasma and CSF and showed single\u2011dose PD activity in humans. \ue200cite\ue202turn0search3\ue201 2) Alzheimer\u2019s & Dementia (conference/abstract) reporting PK/PD relationships and that single oral doses produced dose\u2011dependent reductions in plasma A\u03b2 (and compartmental PK/PD comparisons between rodent and human). \ue200cite\ue202turn0search1\ue201 3) ACS Chemical Neuroscience summary and lead optimization description of GSI\u2011953 (begacestat) with preclinical and early human data supporting APP\u2011selective \u03b3\u2011secretase inhibition and A\u03b2 lowering. \ue200cite\ue202turn0search0\ue201 4) MedChemExpress compound summary giving potency/IC50 and in vivo A\u03b2 lowering data for begacestat. \ue200cite\ue202turn0search4\ue201"
    ]
}